TRxADE HEALTH, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
June 26, 2024 at 02:51 pm
Share
TRxADE HEALTH, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net income was USD 21.25 million compared to net loss of USD 0.677953 million a year ago. Basic loss per share from continuing operations was USD 6.4 compared to USD 1.69 a year ago.
Diluted loss per share from continuing operations was USD 6.4 compared to USD 1.69 a year ago. Basic earnings per share was USD 20.49 compared to basic loss per share of USD 1.01 a year ago.
TRxADE Health, Inc. provides a technology-enabled health services platform. The Company is focused on digitalizing the retail pharmacy and health services experience by optimizing drug procurement, the prescription journey, access to physicians in the patientâs home and patient engagement in the United States. The Companyâs segments include Trxade, Inc., Integra Pharma Solutions, LLC (IPS) and Superlatus. Trxade, Inc. segment provides a web-based pharmaceutical marketplace platform-business to business (B2B) sales. IPS is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. The Superlatus segment holds Sapientiaâs intellectual property for advanced food extrusion technology and The Urgent Company, which is a manufacturer of ice cream that is animal product-free, vegan, lactose-free, and made with plant-B2B sales. Its subsidiaries include Community Specialty Pharmacy, LLC, Alliance Pharma Solutions, LLC, Bonum Health, LLC and others.
TRXADE HEALTH, INC. 
